Shopping Cart
- Remove All
Your shopping cart is currently empty
(49)
By Tag- C-His-Avi
- N-His(6)
- N-GST(2)
- C-Myc(1)
- N-10xHis(1)
- N-His-Avi(1)
Filter
Applied FilterClear all
By Tag By Expression System- HEK293 Cells(37)
- E. coli(21)
- Baculovirus Insect Cells(1)
By Species- Human(57)
- HCV(1)
- Salmonella enteritidis(1)
By SPR-compatible Buffer- Ready-to-use(48)
- Buffer exchange required(10)
- Buffer-exchangeable(1)
Filter
Search Result
Results for "
ns 3
" in TargetMol Product Catalog- Inhibitors & Agonists11
- Peptide Products1
- Natural Products1
- Recombinant Protein59
- Antibody Products1
CompareNS3
TMPY-00323
HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3 NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. One of the HCV proteases, NS3-4A serine protease, is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein) and is responsible for cleavage at four sites of the HCV polyprotein.
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPU-00001
Expression system: E. coli
Length: 1-169, Partial
Activity: BLI
Length: 1-169, Partial
Activity: BLI
Inquiry
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04113
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04116
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06056
Expression system: E. coli
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (natural variant), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06138
Expression system: E. coli
Length: 2-185, Full Length of Mature Protein
Activity: Not Tested
Length: 2-185, Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06345
Expression system: E. coli
Length: 2-185 (mutation), Full Length of Mature Protein
Activity: Not Tested
Length: 2-185 (mutation), Full Length of Mature Protein
Activity: Not Tested
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01399
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01400
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01401
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01402
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01403
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01404
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01407
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01408
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01427
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01428
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01429
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01430
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01431
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01432
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01433
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01434
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01435
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
Go to page 1
Page of 2
Product Comparison
| Product |
|---|
| Bioactive |
| Species |
| Expression System |
| Tag |
| Accession Number |
| Amino Acid |
| Construction |
| Molecular Weight |
| Endotoxin |
| Formulation |
| Reconstitution |
| Stability & Storage |
| Shipping |
| Research Background |
| Size |
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.